MicroRNAs as mediators of drug toxicity

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 377-400

  Yokoi, Tsuyoshi ^a   Nakajima, Miki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

P450; polymorphism; posttranscriptional regulation; toxicology; transcriptional factor

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 1B1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DICLOXACILLIN; DRUG METABOLIZING ENZYME; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FLUTAMIDE; GENOMIC DNA; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IRINOTECAN; MICRORNA; MUTAGENIC AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; UNTRANSLATED RNA; VITAMIN D RECEPTOR;

EPIGENETICS; HUMAN; INFLAMMATION; LIVER INJURY; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; XENOBIOTIC METABOLISM;

ANIMALS; DRUG TOXICITY; HUMANS; METABOLIC DETOXICATION, DRUG; MICRORNAS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84872259086     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140250     Document Type: Review

References (139)

1. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. 2003. New microRNAs from mouse and human. RNA 9:175-79
2. Hinske LC, Galante PA, Kuo WP, Ohno-Machado L. 2010. A potential role for intragenic miRNAs on their hosts' interactome. BMC Genomics 11:533
3. Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92-105
4. Kloosterman WP, Plasterk RH. 2006. The diverse functions of microRNAs in animal development and disease. Dev. Cell 11:441-50
5. Krol J, Loedige I, Filipowicz W. 2010. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11:597-610
6. Fabian MR, Sonenberg N, Filipowicz W. 2010. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79:351-79
7. Chekulaeva M, Filipowicz W. 2009. Mechanism of miRNA-mediated post-transcriptional regulation in animal cells. Curr. Opin. Cell Biol. 21:452-60
8. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 2006. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140-44
9. Jones AL, Roberts RC, Coughtrie MW. 1993. The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein. Biochem. J. 296:287-90
10. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115:787-98
11. Krek A, Gr?un D, Poy MN, Wolf R, Rosenberg L, et al. 2005. Combinatorial microRNA target predictions. Nat. Genet. 37:495-500
12. Baek D, Vill?en J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. Nature 455:64-71
13. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433:769-73
14. Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460:479-86
15. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, et al. 1994. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. 269:13092-99
16. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, et al. 1996. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56:2979-84
17. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 1996. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. USA 93:9776-81
18. Henderson IC, Canellos GP. 1980. Cancer of the breast: the past decade. N. Engl. J. Med. 302:17-30
19. Han X, Liehr JG. 1994. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15:997-1000
20. Newbold RR, Liehr JG. 2000. Induction of uterine adenocarcinoma inCD-1mice by catechol estrogens. Cancer Res. 60:235-37
21. Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI. 1999. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett. 139:199-205
22. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, et al. 1997. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57:3026-31
23. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. 2006. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66:9090-98
24. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M, Yokoi T. 2004. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 64:3119-25
25. Lu Y, Cederbaum AI. 2008. CYP2E1 and oxidative liver injury by alcohol. Free Radic. Biol.Med. 44:723-38
26. Bolt HM, Roos PH, Thier R. 2003. The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine. Int. Arch. Occup. Environ. Health 76:174-85
27. Bìeche I, Narjoz C, Asselah T, Vacher S, Marcellin P, et al. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 17:731-42
28. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-23
29. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. 2010. Human CYP2E1 is regulated by miR-378. Biochem. Pharmacol. 79:1045-52
30. Lee DY, Deng Z, Wang CH, Yang BB. 2007. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fs-1 expression. Proc. Natl. Acad. Sci. USA 104:20350-55
31. Hua Z, Lv Q, Ye W, Wong CK, Cai G, et al. 2006. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 1:e116
32. Kimura S, Kozak CA, Gonzalez FJ. 1989. Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping, and induction by 3-methylcholanthrene. Biochemistry 28:3798-803
33. Jalas JR, Hecht SS, Murphy SE. 2005. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem. Res. Toxicol. 18:95-110
34. Kalscheuer S, Zhang X, Zeng Y, Upadhyaya P. 2008. Differential expression of microRNAs in earlystage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone. Carcinogenesis 29:2394-99
35. Corney DC, Flesken-Nikitin A, Godwin AK, WangW, Nikitin AY. 2007. microRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67:8433-38
36. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-34
37. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:210-58
38. Forrester LM, Neal GE, Judah DJ, Glancey MJ, Wolf CR. 1990. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc.Natl. Acad. Sci. USA87:8306-10
39. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ, Guengerich FP. 1989. Role of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7, 8-dihydroxy-7, 8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. 49:6304-12
40. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, et al. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62:162-72
41. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, et al. 2003. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European-and African-American men and women. Pharmacogenetics 13:596-606
42. Rodríguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. 2005. Phenotypegenotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem. Biophys. Res. Commun. 338:299-305
43. Lamba JK, Lin YS, ThummelK, Daly A, Watkins PB, et al. 2002. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-32
44. Martínez-Jimenez CP, Jover R, Donato MT, Castell JV, Gömez-Lechön MJ. 2007. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr. Drug Metab. 8:185-94
45. Takagi S, Nakajima M, Mohri T, Yokoi T. 2008. Post-transcriptional regulation of human pregnane X receptor by microRNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 283:9674-80
46. PanYZ, GaoW, YuAM.2009. MicroRNAs regulateCYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos. 37:2112-17
47. Nagpal S, Na S, Rathnachalam R. 2005. Noncalcemic actions of vitamin Dreceptor ligands. Endocr. Rev. 26:662-87
48. Deeb KK, Trump DL, Johnson CS. 2007. Vitamin D signaling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7:684-700
49. Hicks J, KrasnitzA, Lakshmi B, Navin NE, Riggs M, et al. 2006. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 16:1465-79
50. de Lyra EC, de Silva IA, Katayama ML, Brentani MM, Nonogaki S, et al. 2006. 25(OH)D3 and 1, 25(OH)2D3 serum concentration and breast tissue expression of 1α-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J. Steroid Biochem. Mol. Biol. 100:184-92
51. Carlberg C, Polly P. 1998. Gene regulation by vitamin D3. Crit. Rev. Eukaryot. Gene Expr. 8:19-42
52. Holick MF. 2007. Vitamin D deficiency. N. Engl. J. Med. 357:266-81
53. Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrath J. 2002. Analysis of vitamin D-receptor (VDR) and retinoid X-receptor αin breast cancer. Histochem. J. 34:35-40
54. Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstr öm G, Hellman P. 2006. 25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J. Histochem. Cytochem. 54:355-61
55. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. 2009. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol. 76:702-9
56. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T. 2009. MicroRNA regulates human vitamin D receptor. Int. J. Cancer 125:1328-33
57. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103:2257-61
58. Gonzalez FJ. 2008. Regulation of hepatocyte nuclear factor 4α-mediated transcription. Drug Metab. Pharmacokinet. 23:2-7
59. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. 2007. Role of human hepatocyte nuclear factor 4αin the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab. Pharmacokinet. 22:287-98
60. Takagi S, Nakajima M, Kida K, Yamaura Y, Fukami T, Yokoi T. 2010. MicroRNAs regulate human hepatocyte nuclear factor 4α, modulating the expression of metabolic enzymes and cell cycle. J. Biol. Chem. 285:4415-22
61. Pikuleva IA. 2006. Cytochrome P450s and cholesterol homeostasis. Pharmacol. Ther. 112:761-73
62. Gradin K, McGuire J, Wenger RH, Kvietikova I, Whitelaw ML, et al. 1996. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol. Cell. Biol. 16:5221-31
63. Choi H, Chun YS, Kim SW, Kim MS, Park JW. 2006. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol. 70:1664-71
64. Choi H, Chun YS, Shin YJ, Ye SK, Kim MS, Park JW. 2008. Curcumin attenuates cytochrome P450 induction in response to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin by ROS-dependently degrading AhR and ARNT. Cancer Sci. 99:2518-24
65. Oda Y, NakajimaM, Mohri T, Takamiya M, Aoki Y, et al. 2012. Aryl hydrocarbon nuclear translocator in human liver is regulated by miR-24. Toxicol. Appl. Pharmacol. 260:222-31
66. Adams BD, Furneaux H, White BA. 2007. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α(ERα) and represses ERαmessenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 21:1132-47
67. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. 2008. MicroRNA-221/222 negatively regulates estrogen receptor αand is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 283:31079-86
68. Xiong J, Yu D, Wei N, Fu H, Cai T, et al. 2010. An estrogen receptor αsuppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples. FEBS J. 277:1684-94
69. Pandey DP, Picard D. 2009. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor αmRNA. Mol. Cell. Biol. 29:3783-90
70. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, et al. 2010. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor α in breast cancer cells. Cancer Res. 70:9175-84
71. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, Safe S. 2010. MicroRNA-27a indirectly regulates estrogen receptor αexpression and hormone responsiveness inMCF-7 breast cancer cells. Endocrinology 151:2462-73
72. Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, et al. 2011. PPARα is regulated by miR-21 and miR-27b in human liver. Pharm. Res. 28:2467-76
73. Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, et al. 2009. microRNA miR-27b impairs human adipocyte differentiation and targets PPARγ. Biochem. Biophys. Res. Commun. 390:247-51
74. Jennewein C, von Knethen A, Schmid T, Brune B. 2010. MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated preceptor γ (PPARγ) mRNA destabilization. J. Biol. Chem. 285:11846-53
75. Kim SY, Kim AY, Lee HW, Son YH, Lee GY, et al. 2010. miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARγexpression. Biochem. Biophys. Res. Commun. 392:323-28
76. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. 2009. A role of miR-27 in the regulation of adipogenesis. FEBS J. 276:2348-58
77. Ji J, Zhang J, Huang G, Qian J, Wang X, Mei S. 2009. Over- expressedmicroRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation. FEBS Lett. 583:759-66
78. Imai T, Jiang M, Chambon P, Metzger D. 2001. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor α mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. Proc. Natl. Acad. Sci. USA 98:224-28
79. Rezen T, Rozman D, Pascussi JM, Monostory K. 2011. Interplay between cholesterol and drug metabolism. Biochim. Biophys. Acta 1814:146-60
80. Liu X, Yu J, Jiang L, Wang A, Shi F, et al. 2009. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) andmanganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics 6:131-39
81. Xu Y, Fang F, Zhang J, Josson S, St. Clair WH, St. Clair DK. 2010. mir-17 suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS ONE 12:e14356
82. Taguchi A, Yanagisawa K, Tanaka M, Cao K, Matsuyama Y, et al. 2008. Identification of hypoxiainducible factor-1αas a novel target for miR-17-92 microRNA cluster. Cancer Res. 68:5540-45
83. Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. 2007. Peroxisome proliferatoractivated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell. Biol. 27:4238-47
84. Aono J, Yanagawa T, Itoh K, Li B, Yoshida H, et al. 2003. Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. Biochem. Biophys. Res. Commun. 305:271-77
85. Marsit CJ, Eddy K, Kelsey KT. 2006. MicroRNA responses to cellular stress. Cancer Res. 66:10843-48
86. Fukushima T, Hamada Y, Yamada H, Horii I. 2007. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride: regulating role of micro-RNA for RNA expression. J. Toxicol. Sci. 32:401-9
87. Izzotti A, Larghero P, Longobardi M, Cartiglia C, Camoirano A, et al. 2011. Dose-responsiveness and persistence of microRNA expression alterations induced by cigarette smoke in mouse lung. Mutat. Res. 717:9-16
88. Schembri F, Sridhar S, Perdomo C, Gustafson AM, Zhang X, et al. 2009. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl. Acad. Sci. USA 106:2319-24
89. Moffat ID, Boutros PC, Celius T, Linden J, Pohjanvirta R, Okey AB. 2007. microRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol. Sci. 99:470-87
90. Yoshioka W, Higashiyama W, Tohyama C. 2011. Involvement of microRNAs in dioxin-induced liver damage in the mouse. Toxicol. Sci. 122:457-65
91. Yauk CL, Jackson K, Malowany M, Williams A. 2011. Lack of change in microRNA expression in adult mouse liver following treatment with benzo(a)pyrene despite robust mRNA transcriptional response. Mutat. Res. 722:131-39
92. Malik AI, Williams A, Lemieux CL, White PA, Yauk CL. 2012. Hepatic m RNA, micro RNA, and miR-34a-target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation. Environ. Mol. Mutagen. 53:10-21
93. Halappanavar S, WuD, Williams A, Kuo B, Godschalk RW, et al. 2011. Pulmonary gene and microRNA expression changes in mice exposed to benzo(a)pyrene by oral gavage. Toxicology 285:133-41
94. Li D, Wang Q, Liu C, Duan H, Zeng X, et al. 2012. Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol. Sci. 125:382-91
95. Pohjanvirta R, Tuomisto J. 1994. Short-term toxicity of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in laboratory animals: effects, mechanisms, and animal models. Pharmacol. Rev. 46:483-549
96. Cha YH, Kim NH, Park C, Lee I, Kim HS, Yook JI. 2012. miRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 11:1273-81
97. Chen T, Heflich RH, Moore MM, Mei N. 2010. Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice. Environ. Mol. Mutagen. 51:156-63
98. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-31
99. Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. 2007. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat. Res. 619:30-37
100. Murakami T, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. 2006. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25:2537-45
101. Zhang B, Pan X. 2009. RDX induces aberrant expression microRNAs in mouse brain and liver. Environ. Health Perspect. 117:231-40
102. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. 2011. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat. Res. 717:77-84
103. Chen T, Huang Z, Wang L, Wang Y, Wu F, et al. 2009. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, andORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc. Res. 83:131-39
104. Braconi C, Huang N, Patel T. 2010. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51:881-90
105. BrockM, Trenkmann M, Gay RE, Michel BA, Gay S, et al. 2009. Interleukin-6modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 104:1184-91
106. LofflerD, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackerm uller J, et al. 2007. Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110:1330-33
107. Nahid MA, Pauley KM, Satoh M, Chan EK. 2009. miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J. Biol. Chem. 284:34590-99
108. Nahid MA, Satoh M, Chan EK. 2011. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J. Immunol. 186:1723-34
109. Sun Y, Varambally S, Maher CA, Cao Q, Chockley P, et al. 2012. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood 117:6172-83
110. Kobayashi E, Kobayashi M, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2009. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol. Sci. 111:302-10
111. Kobayashi M, Higuchi S, Mizuno K, Tsuneyama K, Fukami T, et al. 2010. Interleukin-17 is involved in α-naphthylisothiocyanate-induced liver injury in mice. Toxicology 275:50-57
112. Yano A, Higuchi S, Tsuneyama K, Fukami T, Nakajima M, Yokoi T. 2012. Involvement of immunerelated factors in diclofenac-induced acute liver injury in mice. Toxicology 293:107-14
113. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, et al. 1993. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol. 44:707-15
114. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, et al. 2000. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem. Biophys. Res. Commun. 274:707-13
115. Higuchi S, Kobayashi M, Yano A, Tsuneyama K, Fukami T, et al. 2012. Involvement of Th2 cytokines in the mouse model of flutamide-induced liver injury. J. Appl. Toxicol. 32:815-22
116. Higuchi S, Kobayashi M, Yoshikawa Y, Tsuneyama K, Fukami T, et al. 2011. IL-4 mediates dicloxacillininduced liver injury in mice. Toxicol. Lett. 200:139-45
117. Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC. 2003. SNP and haplotype variation in the human genome. Mutat. Res. 526:53-61
118. Iwai N, Naraba H. 2005. Polymorphisms in human pre-miRNAs. Biochem. Biophys. Res. Commun. 331:1439-44
119. Duan R, Pak C, Jin P. 2007. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum. Mol. Genet. 16:1124-31
120. Saunders MA, Liang H, Li WH. 2007. Human polymorphism at microRNAs and microRNA target sites. Proc. Natl. Acad. Sci. USA 104:3300-5
121. Boni V, Zarate R, Bandres E, Gomez MA, Maiello E, et al. 2011. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J. 11:429-36
122. Sethupathy P, Collins FS. 2008. MicroRNA target site polymorphisms and human disease. Trends Genet. 24:489-97
123. Mishra PJ, Bertino JR. 2009. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10:399-416
124. Yu X, Dhakal IB, Beggs M, Edavana VK, Williams S, et al. 2010. Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol. Sci. 118:391-403
125. Richardson K, Lai CQ, Parnell LD, Lee YC, Ordovas JM. 2011. A genome-wide survey for SNPs altering microRNA seed sites identifies functional candidates in GWAS. BMC Genomics 12:504
126. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GA, Banerjee D, Bertino JR. 2007. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads tomethotrexate resistance. Proc. Natl. Acad. Sci. USA 104:13513-18
127. Sun C, Southard C, Olopade OI, Di Rienzo AD. 2011. Differential allelic expression of c.1568C A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3-UTR. Gene 481:24-28
128. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm oller J, et al. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-78
129. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. 2008. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141:672-75
130. Etheridge A, Lee I, Hood L, Galas D, Wang K. 2011. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 717:85-90
131. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. 2009. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc. Natl. Acad. Sci. USA 106:4402-7
132. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al. 2009. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 55:1977-83
133. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, et al. 2010. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 56:1830-38
134. Yamaura Y, NakajimaM, Takagi S, FukamiT, Tsuneyama K, Yokoi T. 2012. Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS ONE 7:e30250
135. Yang X, Greenhaw J, Shi Q, Su Z, Qian F, et al. 2012. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol. Sci. 125:335-44
136. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, et al. 2011. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54:1767-76
137. Vreugdenhil E, Verissimo CS, Mariman R, Kamphorst JT, Barbosa JS, et al. 2009. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 150:2220-28
138. Yang M, Yao Y, Eades G, Zhang Y, Zhou Q. 2011. miR-28 regulates Nrf2 expression through a Keap1-independent mechanism. Breast Cancer Res. Treat. 129:983-91
139. Eades G, Yang M, Yao Y, Zhang Y, Zhou Q. 2011. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J. Biol. Chem. 286:40725-33